Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $46.43 Average PT from Brokerages

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have received an average rating of “Buy” from the ten research firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $46.4286.

AAPG has been the subject of a number of recent research reports. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial started coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st.

Ascentage Pharma Group International Trading Down 2.0%

Shares of NASDAQ:AAPG opened at $15.54 on Monday. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. Ascentage Pharma Group International has a 12 month low of $15.02 and a 12 month high of $40.47. The company has a 50-day moving average price of $17.54 and a 200 day moving average price of $20.00.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. As a group, research analysts expect that Ascentage Pharma Group International will post -2.42 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.